<prompt> Please answer with one of the option in the bracket. Write reasoning in between . Write answer in between .Q:A 43-year-old man presents with a severe, throbbing, left-sided headache for the last 2 hours. He says that the pain has been progressively worsening and is aggravated by movement. The patient says he has had similar episodes in the past and would take acetaminophen and sleep it off. He also complains that the light in the room is intolerably bright, and he is starting to feel nauseous. No significant past medical history and no current medications. Vital signs include: pulse 110min, respiratory rate 15min, and blood pressure 13686 mm Hg. Physical examination reveals mild conjunctival injection in the left eye. Intraocular pressure IOP is normal. The rest of the examination is unremarkable. The patient is given a medication which relieves his symptoms. During discharge, he wants more of this medication to prevent episodes in future but he is told that the medication is only effective in terminating acute attacks but not for prevention. Which of the following receptors does the drug given to this patient bind to?? A: β-adrenergic receptors, B: 5-hydroxytryptamine type 1 5-HT1 receptors, C: Angiotensin II receptors, D: 5-hydroxytryptamine type 2 5-HT2 receptors, E: Muscarinic receptors,  <response>: This is a clinical vignette describing a patient with a severe, throbbing headache aggravated by movement, photophobia, nausea, and a history of similar episodes relieved by sleep. This presentation is classic for migraine headache. The question asks about the receptor that the medication given to the patient binds to. Based on the clinical information provided, the medication was able to rapidly relieve the patients migraine symptoms. This effect is consistent with a medication that binds to 5-HT1 receptors, such as sumatriptan or other triptan medications used for acute migraine treatment. The other answer choices describe receptors for medications that would not be appropriate for acute migraine relief in this clinical scenario.B: 5-hydroxytryptamine type 1 5-HT1 receptors 